Best Growth Stocks to Buy for October 23rd

Zacks highlighted three stocks with a #1 (Strong Buy) rank: Ultrapar Participacoes, Petco Health and Wellness, and monday.com. Current-year consensus earnings estimates rose over the prior 60 days by 11.5%, 26.3%, and 1.5%, respectively; the article reports no share-price reaction.

Analysis

Treat this as a screen-generated estimate-revision signal, not a fresh fundamental catalyst: analyst upgrades can already be reflected in prices, and the article supplies no valuation, share-price reaction, or operating data to assess earnings quality. The revisions are not comparable across these businesses. For WOOF, test whether estimates are supported by comparable sales, customer retention, and cash generation; if not, a squeeze in expectations could expose the stock to downside against better-capitalized online and retail competitors such as Chewy. For UGP, earnings sensitivity to Brazilian real moves, input costs, and local pricing can overwhelm estimate momentum; currency or petrochemical volatility is a key offset. MNDY’s modest revision signal makes the “growth” label less actionable without evidence of accelerating customer growth, retention, or margins; competitive pressure from Microsoft and Atlassian is a watch item, not proof of lost share.

Near term (days), the main risk is a transient reaction to the ranking article. Over 1–3 months, earnings reports and guidance can validate or reverse revisions. Over 6–18 months, the differentiators are WOOF’s ability to sustain cash generation, UGP’s resilience to Brazilian macro and input-cost swings, and MNDY’s durable software growth. No outright position is justified from this information alone. Falsify the positive read if estimates reverse, guidance weakens, or the relevant operating metrics deteriorate; verify valuation and price action before sizing any trade.

Key Decisions for Investors

• Do not buy the three names as a basket on the ranking alone; the signal lacks valuation, price-action, and fundamental confirmation.
• Put WOOF on an earnings watch: require evidence in comparable sales, customer retention, and cash generation before considering a long; reassess if estimates are cut or operating metrics weaken.
• For UGP, monitor Brazilian-real exposure and input-cost/pricing trends alongside estimate revisions. Treat adverse FX or petrochemical volatility as a thesis warning, not a reason to extrapolate revisions.
• For MNDY, wait for confirmation in growth, retention, and margins before taking a directional position; its limited revision momentum does not independently support a growth premium.